EFTA00937845.pdf

From: Jeffrey Epstein To: Cecile de Jongh >, Jeffrey Epstein <jeevacation®gmail.com> Subject: Fwd: Your news release today on Alzheimers and cyclophilin - bit more info you might want to know Date: Tue, 19 Jun 2012 02:36:13 +0000 Attachments: Pharmaceutical Fonnulation_&_Quality_TBI_August_September 2011.pdf Hi Jeffrey and Cecile, This came as a result of my press release on Alzheimer's. It sounds interesting. Forwarded message From: Steve Campbell Date: Mon, Jun 18, 2012 at 7:17 PM Subject: Your news release today on Alzheimers and cyclophilin - bit more info you might want to know To: Hi, Please consider passing this on to Jeffrey or his science advisors. After I read the foundation's news release today on cyclophilin's impact on Alzheimer's and cylosporine, I thought they may be interested in what my client is doing. My client is a small relatively unknown Swedish pharmaceutical company called NeuroVive Pharma www.neurovive.com who are world leaders in cyclophilin inhibitors. They have asked me to help build their profile in North America. I would like to introduce you to them. NeuroVive is a world leader in the application of cyclosporine as a cyclophilin inhibitor. They have two cycosporine-based drugs in advanced clinical study for traumatic brain injury - TBI (in phase II clinical study) and one for reperfusion injury in heart attack (phase III clinical study). These cyclophilin-inhibiting drugs are finished products and just need to obtain regulatory approval. NeuroVive also has an advanced discovery and R&D program with second- and third-generation cyclophilin inhibitors showing great promise in stroke, mitochondrial energy restoration and regulation and other areas. It also turns out that cyclophilins are involved in many different neurodegeneration diseases (Alzheimers, ALS, MS, etc.). Also in traumatic brain injury, heart attack and stroke. NeuroVive's research program in cyclophilin inhibitors is likely the world's most advanced, not only in terms of research but also importantly in terms of developing pharmaceutical products that are close to helping millions of people suffering brain injuries and heart attacks. As a small company, they can always put funding to great use in speeding up the research and development (and regulatory approval) of their cyclophilin inhibitors. NeuroVive's cyclopsorine-based traumatic brain injury pharmaceutical, called NeuroSTAT, reduces brain damage in animals by 80%. One magazine called cyclosporine "TBI's Miracle Drug." A PDF of that article is attached. (They asked NeuroVive to write an article and I wrote that footnoted article. The headline was the editor's). It explains why inhibiting cyclophilins are so important. EFTA00937845 NeuroSTAT is in phase II/III adaptive clinical study in Europe. Adaptive means it will be converted to a phase III if early results are promising. It is two to five years away from approval (after almost two decades in development). In my opinion, we need to speed up this approval process if at all possible. In heart attack, this same medicine but called CicloMulsion for the heart attack market has been shown to reduce muscle damage from reperfusion injury in humans by 40% in a small-group study (New England Journal of Medicine 2008). The phase III study in heart attack is underway in Europe in a study organized by independent investigators (NeuroVive is only providing product and placebo for this study). If the Jeffrey Epstein Foundation was interested there are a few ways it could help NeuroVive push cyclophilin inhibitors along faster. I. It could help by driving funding to start and speed up US clinical studies for NeuroSTAT. To get it approved closer to two years, rather than the projected five. The Foundation could consider funding or leading the funding of a phase II or III study in the US. There are a number of American universities NeuroVive is working with currently. Not only would approval for the TBI pharmaceutical help millions of brain-injured people annually worldwide sooner beginning in years 3, 4 or 5, the approval of this TBI pharmaceutical would likely spark greatly expanded global research efforts into cyclophilin inhibitors and their effect on Alzheimers and the other neurodegenerative diseases. In other words, the initial investment by the Jeffrey Epstein Foundation would be greatly leveraged by all the subsequent investment flows into this very promising area of medical research. 2. The Foundation could provide funding to expand NeuroVive's research into its second- and third-generation cyclophilin inhibitors. If these are of interest or if you would just like to have a short presentation from NeuroVive's CEO on their research program, please let me know. Thank you. Steve Campbell Steve Campbell, APR Campbell & Company Strategies Inc. Communications and Public Relations Vancouver, B.C. Canada 01 (office) 01 fax) aSl www.campbellpr.bc.ca Referrals are the ultimate compliment! Please share our contact information with anyone who may benefit from our services. EFTA00937846